Osmotica Pharmaceuticals plc (OSMT) and Its Competitors Financial Results Comparison

As Biotechnology company, Osmotica Pharmaceuticals plc (NASDAQ:OSMT) is competing with its competitors based on the analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Institutional and Insider Ownership

Osmotica Pharmaceuticals plc has 37% of its shares owned by institutional investors vs. an average of 50.88% institutional ownership for its peers. On other hand Osmotica Pharmaceuticals plc has 41.8% of its shares owned by company insiders vs. an average of 8.18% insiders ownership for its peers.


Table 1 has Osmotica Pharmaceuticals plc and its peers’ return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Osmotica Pharmaceuticals plc -2.33% 0.00% 0.00%
Industry Average 1,464.25% 88.44% 21.62%

Valuation & Earnings

In next table we are comparing Osmotica Pharmaceuticals plc and its peers’ net profit, top-line revenue and valuation.

Net Income Gross Revenue Price/Earnings Ratio
Osmotica Pharmaceuticals plc 6.40M 274.34M 0.00
Industry Average 34.08M 2.33M 58.78

Analyst Recommendations

Table 3 provides summary of current ratings for Osmotica Pharmaceuticals plc and its peers.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Osmotica Pharmaceuticals plc 0 0 0 0.00
Industry Average 1.17 1.78 2.01 2.68

As a group, Biotechnology companies have a potential upside of 173.20%.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Osmotica Pharmaceuticals plc and its peers.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Osmotica Pharmaceuticals plc -0.38% -11% 0% 0% 0% -3.68%
Industry Average 9.08% 15.16% 32.92% 41.89% 74.81% 65.27%

For the past year Osmotica Pharmaceuticals plc had bearish trend while Osmotica Pharmaceuticals plc’s peers had bullish trend.


Osmotica Pharmaceuticals plc has a Current Ratio of 1.3 and a Quick Ratio of 1.1. Competitively, Osmotica Pharmaceuticals plc’s competitors Current Ratio is 7.68 and has 7.52 Quick Ratio. Osmotica Pharmaceuticals plc’s competitors have better ability to pay short and long-term obligations than Osmotica Pharmaceuticals plc.


Osmotica Pharmaceuticals plc does not pay a dividend.


Osmotica Pharmaceuticals plc’s competitors show that they’re better in 4 of the 4 factors compared to the company itself.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.